Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAdvanced Health ESA Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentAdvanced HealthPolicy N/A

    Erythropoiesis-Stimulating Agent (ESA) Coverage Guideline

    Customize your policy alerts

    Sign up for all advancedhealth policy alerts

    Know when advancedhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs coverage of erythropoiesis-stimulating agents for anemia associated with cancer chemotherapy, myelodysplasia, HIV/AIDS, and chronic renal failure. Coverage depends on hemoglobin or hematocrit thresholds, condition-specific requirements, reassessment, treatment response, and hemoglobin limits.

    Policy Summary
    PayerAdvanced Health
    PolicyErythropoiesis-Stimulating Agent (ESA) Coverage Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDiscontinue treatment if there is no response at the required reassessment interval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <10 g/dLESA anemia threshold
    8 weeksChemotherapy, myelodysplasia, or HIV/AIDS reassessment
    12 weeksChronic renal failure reassessment
    ≤11 g/dLMaximum responsive hemoglobin
    <500 IU/LHIV/AIDS EPO requirement

    Condition-Specific Coverage Criteria

    Cancer chemotherapy or myelodysplasia-associated anemia

    Covered when the patient has qualifying anemia and the applicable condition-specific requirements are met.

    • Qualifying condition

      • Anemia is induced by cancer chemotherapy given within the previous 8 weeks.
      • Anemia occurs in the setting of myelodysplasia.
    • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%

    HIV/AIDS-associated anemia

    Covered when all of the following requirements are met.

    Policy Summary
    PayerAdvanced Health
    PolicyErythropoiesis-Stimulating Agent (ESA) Coverage Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDiscontinue treatment if there is no response at the required reassessment interval.
    SourceLink
    On This Page
    Condition-Specific Coverage CriteriaThresholds and Treatment LimitsReassessment and Discontinuation RequirementsPolicy ScopeKey TermInitial ESA TherapyResponse-Based Continuation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    • Anemia is associated with HIV/AIDS.
    • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%
    • The endogenous erythropoietin level is less than 500 IU/L.EPO <500 IU/L
    • The patient is not receiving zidovudine (AZT) above 4,200 mg per week.Zidovudine ≤4,200 mg/week

    Chronic renal failure-associated anemia

    Covered when all of the following requirements are met.

    • Anemia is associated with chronic renal failure, with or without dialysis.
    • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%

    Thresholds and Treatment Limits

    Anemia threshold
    Hemoglobin thresholdHgb < 10 g/dL
    Hematocrit thresholdHct < 30%
    Applies toQualifying anemia associated with recent cancer chemotherapy, myelodysplasia, HIV/AIDS, or chronic renal failure
    HIV/AIDS endogenous erythropoietin level
    Required endogenous erythropoietin level< 500 IU/L
    Applicable conditionHIV/AIDS-associated anemia
    Treatment requirementAn endogenous erythropoietin level below 500 IU/L is required for treatment
    HIV/AIDS zidovudine dose
    MedicationZidovudine (AZT)
    Maximum dose4,200 mg per week
    Treatment requirementThe patient may not be receiving zidovudine above 4,200 mg per week
    Responsive HIV/AIDS or dialysis-associated anemia
    Applicable conditionsResponsive HIV/AIDS-associated anemia or chronic renal failure-associated anemia with dialysis
    Hemoglobin limitHgb should not exceed 11 g/dL
    Dose approachUse the lowest ESA dose sufficient to reduce the need for RBC transfusions
    Responsive non-dialysis chronic renal failure-associated anemia
    Applicable conditionResponsive chronic renal failure-associated anemia in patients not on dialysis
    Hemoglobin limitHgb should not exceed 10 g/dL
    Dose approachUse the lowest ESA dose sufficient to reduce the need for RBC transfusions
    Chemotherapy-associated anemia response
    Discontinuation thresholdDiscontinue ESA therapy once Hgb reaches 10 g/dL
    ExceptionA lower hemoglobin level may be sufficient to avoid the need for RBC transfusion
    ReassessmentReassess after 8 weeks of treatment; discontinue treatment if there is no response

    Reassessment and Discontinuation Requirements

    Denial Risk

    No Response at Reassessment

    Reassess response at the applicable interval. If there is no response, discontinue ESA treatment.

    • Cancer chemotherapy-induced anemia or myelodysplasia: reassess after 8 weeks.
    • HIV/AIDS-associated anemia: reassess after 8 weeks.
    • Chronic renal failure-associated anemia, with or without dialysis: reassess after 12 weeks.
    Documentation Required

    HIV/AIDS Requirements Must Be Met

    For ESA treatment of HIV/AIDS-associated anemia, all applicable requirements must be satisfied before treatment is continued.

    • Anemia must be documented as Hgb < 10 gm/dl or Hct < 30%.
    • Endogenous erythropoietin level must be < 500 IU/L.
    • The patient must not be receiving zidovudine (AZT) at a dose greater than 4,200 mg/week.
    • Reassess after 8 weeks; discontinue treatment if there is no response.
    • If there is a response, use the lowest ESA dose sufficient to reduce the need for RBC transfusions, and do not allow Hgb to exceed 11 gm/dl.
    Denial Risk

    Hemoglobin Ceiling Reached

    Discontinue or dose-limit ESA therapy when the applicable hemoglobin ceiling is reached, unless the guideline expressly permits a lower level to avoid RBC transfusion.

    • Cancer chemotherapy-induced anemia or myelodysplasia: discontinue once Hgb reaches 10 gm/dl, unless a lower Hgb is sufficient to avoid RBC transfusion.
    • HIV/AIDS-associated anemia: use the lowest effective ESA dose; Hgb must not exceed 11 gm/dl.
    • Chronic renal failure: use the lowest effective ESA dose; Hgb must not exceed 11 gm/dl, or 10 gm/dl in patients not on dialysis.

    Policy Scope

    This guideline addresses erythropoiesis-stimulating agent (ESA) treatment for qualifying anemia associated with recent cancer chemotherapy, myelodysplasia, HIV/AIDS, or chronic renal failure. ESA therapy is intended to reduce the need for red blood cell transfusions while avoiding excessive hemoglobin elevation. Coverage requires condition-specific eligibility, reassessment of treatment response, and dose adjustment or discontinuation when applicable hemoglobin limits are reached.

    Key Term

    ESA
    TermErythropoiesis-stimulating agents (ESAs)
    Primary roleTreat qualifying anemia
    Treatment goalReduce the need for red blood cell transfusions

    Initial ESA Therapy

    Initial ESA therapy

    Initial ESA treatment is indicated when the patient meets one of the following covered indications and has qualifying anemia.

    Covered indications

    • Cancer chemotherapy or myelodysplasia

      • Qualifying condition

        • Anemia is induced by cancer chemotherapy given within the previous 8 weeks.
        • Anemia occurs in the setting of myelodysplasia.
      • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%

    • HIV/AIDS-associated anemia

      • Anemia is associated with HIV/AIDS.
      • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%
      • The endogenous erythropoietin level is less than 500 IU/L.EPO <500 IU/L
      • The patient is not receiving zidovudine (AZT) above 4,200 mg per week.Zidovudine ≤4,200 mg/week

    • Chronic renal failure-associated anemia

      • Anemia is associated with chronic renal failure, with or without dialysis.
      • Hemoglobin is less than 10 g/dL or hematocrit is less than 30%.Hgb <10 g/dL or Hct <30%

    Response-Based Continuation

    Response-based continuation

    Continue ESA therapy only when reassessment demonstrates a response and the hemoglobin remains within the applicable limit.

    Condition-specific continuation

    • Chemotherapy-, myelodysplasia-, or HIV/AIDS-associated anemia

      • Reassess after 8 weeks of treatment.8 weeks
      • A response to treatment is demonstrated; discontinue treatment if there is no response.
      • For chemotherapy-associated anemia, discontinue the ESA once hemoglobin reaches 10 g/dL unless a lower hemoglobin level is sufficient to avoid the need for red blood cell transfusion.Hgb 10 g/dL for discontinuation unless a lower level avoids RBC transfusion
      • For HIV/AIDS-associated anemia, use the lowest ESA dose sufficient to reduce the need for red blood cell transfusions and keep hemoglobin at or below 11 g/dL.Hgb ≤11 g/dL

    • Chronic renal failure-associated anemia

      • Reassess after 12 weeks of treatment.12 weeks
      • A response to treatment is demonstrated; discontinue treatment if there is no response.
      • Use the lowest ESA dose sufficient to reduce the need for red blood cell transfusions and keep hemoglobin at or below 11 g/dL.Hgb ≤11 g/dL
      • In patients not on dialysis, hemoglobin must not exceed 10 g/dL.Hgb ≤10 g/dL when not on dialysis